Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01552603 · ClinicalTrials.gov registry record · Phase 2
Artificial Pancreas Control System in an Inpatient Setting
A Phase 2 study, sponsored by Legacy Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT01552603 is a Phase 2 study that has completed, run by Legacy Health System. The registered enrollment target is 14 participants.
The verdict
NCT01552603, a Phase 2 study, has completed, sponsored by Legacy Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to verify an automated system of blood glucose control in Type I Diabetics. The automated system consists of the investigational Artificial Pancreas Control software (APC), two blood glucose sensors, and two hormone pumps, one for delivering insulin to lower blood sugar, and the second for delivering glucagon to raise blood sugar. The blood glucose sensors relays information to the Artificial Pancreas software, which uses the Adaptive Proportional Device algorithm to determine the rate of insulin and glucagon infusion by the hormone pumps. In prior studies, the Adaptive Proportional Device algorithm has been verified, but required manual input into the computer and hormone pumps. This study differs in that it uses a fully automated system under the control of the Artificial Pancreas Control software. The importance of this change is that it is the next step to enable outpatient use of automated, closed loop blood glucose control.
Interventions
- DEVICE Artificial Pancreas Control Software
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-03 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01552603
The ClinicalTrials.gov registry entry for NCT01552603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Legacy Health System, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Artificial Pancreas Control Software is the first listed.
NCT01552603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01552603 about?
NCT01552603 is a clinical study titled "Artificial Pancreas Control System in an Inpatient Setting". The purpose of this study is to verify an automated system of blood glucose control in Type I Diabetics. The automated system consists of the investigational Artificial Pancreas Control software (APC), two blood glucose sensors, and two hormone pumps, one for delivering insulin to lower blood sugar,...
What is the current status of trial NCT01552603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01552603?
The interventions under investigation include: Artificial Pancreas Control Software (DEVICE).
Who is sponsoring clinical trial NCT01552603?
This trial is sponsored by Legacy Health System, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.